Skip to main content

Table 1 Patient and Treatment Characteristics

From: Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases

Variable

n

%

No. of Patients

16

 

Treatment Sessions

18

 

No. of Lesions

40

 

F/U from RT (months)

 Median (range)

13.2 (0.1–55.5)

 

F/U from Brain Metastases Diagnosis (months)

 Median (range)

68.6 (16.5–249)

 

Age at time of RT

 Median (range)

56 (40–85)

 

KPS

 100

2

13%

 90

10

63%

 80

4

25%

Lesions Treated Per Patient

 Median (range)

2 (1–6)

 

Receptors

 HR+/HER2+

10

63%

 HR−/HER2+

6

38%

Concurrent Therapy with SRS

 None

9

50%

 Chemotherapy

1

5%

 TP

2

11%

 Chemotherapy + TP

2

11%

 ET

2

11%

 ET + TKI + TP

1

5%

 ET + TP

1

5%

  1. Abbreviations: F/U = follow up, RT = radiation therapy, KPS = Karnofsky performance status, TKI = tyrosine kinase inhibitor, ET = endocrine therapy, TP = trastuzumab and/or pertuzumab, HR = hormone receptor, SRS = stereotactic radiosurgery